These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 10760075)
1. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Delyani JA Kidney Int; 2000 Apr; 57(4):1408-11. PubMed ID: 10760075 [TBL] [Abstract][Full Text] [Related]
2. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Moore TD; Nawarskas JJ; Anderson JR Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934 [TBL] [Abstract][Full Text] [Related]
3. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Takeda Y Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460 [TBL] [Abstract][Full Text] [Related]
5. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard? Jewell CW; Watson LE; Mock J; Dostal DE Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023 [TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone receptor antagonist (SARA). Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Sica DA Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888 [TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone. Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746 [TBL] [Abstract][Full Text] [Related]
11. Eplerenone for the treatment of cardiovascular disorders. Watanabe M; Krum H Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915 [TBL] [Abstract][Full Text] [Related]
12. The resurrection of spironolactone on its golden anniversary. Futterman LG; Lemberg L Am J Crit Care; 2004 Mar; 13(2):162-5. PubMed ID: 15043244 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Hu X; Li S; McMahon EG; Lala DS; Rudolph AE Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407 [TBL] [Abstract][Full Text] [Related]
15. The role of aldosterone receptor blockade in the management of cardiovascular disease. Liew D; Krum H Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020 [TBL] [Abstract][Full Text] [Related]
16. Aldosterone receptor antagonists for hypertension: what do they offer? Liew D; Krum H Drugs; 2003; 63(19):1963-72. PubMed ID: 12962513 [TBL] [Abstract][Full Text] [Related]